Italian blood donors with anti-HBc and occult hepatitis B virus infection

Haematologica

Volumn 92, Issue 12, 2007, Pages 1664-1670

  Manzini, Paola ^a,k   Girotto, Mauro ^b   Borsotti, Raffaele ^c   Giachino, Osvaldo ^d   Guaschino, Roberto ^e   Lanteri, Maurizio ^f   Testa, Domenico ^g   Ghiazza, Paola ^h   Vacchini, Maria ⁱ   Danielle, Franca ^a   Pizzi, Alessandra ^a   Valpreda, Chiara ^a   Castagno, Franco ^a   Curti, Franco ^a   Magistroni, Paola ^j   Abate, Maria Lorena ^j   Smedile, Antonina ^j   Rizzetto, Mario ^j  

^a A O S Giovanni Battista di Torino ^*  (Italy)

^b Ospedale di Ivrea   (Italy)

^c ASL 14   (Italy)

^d AS Torino 4   (Italy)

^e Mediana Trasfusionale ed Immunoematologia   (Italy)

^f Servizio di Immunoematologia e Trasfusionale   (Italy)

^g Ospedale SS Annunziata   (Italy)

^h OIRM di Torino   (Italy)

ⁱ MAGGIORE HOSPITAL   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k AO S Giovanni Battista di Torino   (Italy)

more..

Author keywords

Anti HBc; Blood donors; HBV; HBV DNA+ blood units; Hepatitis B virus; Occult HBV infection

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; BLOOD DONOR; DEVICE; FEMALE; HEPATITIS B; HETEROZYGOTE DETECTION; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; SCREENING; VASCULARIZATION; VIREMIA;

BLOOD DONORS; COHORT STUDIES; DNA, VIRAL; DONOR SELECTION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; ITALY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 37049024106     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11224     Document Type: Article

References (30)

1. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Eurosurveillance 2005;10:9-10.
2. Pillonel J, Laperche S, and l'Etablissement Francais du Sang. Trends in risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Eurosurveillance 2005;10:5-6.
3. Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchino E, Ragni P, et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000;33:980-5.
4. Tosti ME, Solinas S, Prati D, Salvaneschi L, Manca M, Francescani M, et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002;117:215-9.
5. Velati C, Formiatti L, Baruffi L, Romano' L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in three years following implementation (2001-2003). Eurosurveillance 2005;10:3-4.
6. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70.
7. Sanchez-Quijano A, Jaureugui JI, Leal M, Pineda JA, Castilla A, Abad MA, et al. Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993;17:288-93.
8. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000;32:249-52.
9. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000;31:488-95.
10. Yotsuyanagy H, Yasuda K, Moriya K, Shintani Y, Fujie H, Tsutsumi T, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion 2001: 41:1093-9.
11. Henning H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2002; 100:2637-41.
12. Dreier J, Kroger M, Diekmann C, Gotting C, Kleesiek K. Low-level viremia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 2004;14:97-103.
13. Main JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBVDNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999;issue 186-95.
14. Hoofnagle JH, Seefe LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978;298:1379-83.
15. Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995;35:5-12.
16. Soldan K, Ramsay M, Collins M. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: teview of database. Br Med J 1999;318:95.
17. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 2001;41:878-84.
18. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999;29:976-84.
19. Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001;39:362-4.
20. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003;101:2419-25.
21. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, et al. Frequency of HBV-DNA detection in US blood donors testing positive for the presence of anti-HBc: implication for transfusion transmission and donor screening. Transfusion 2003; 43:696-704.
22. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc scteening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 2001; 41:652-8.
23. Bernvill SS, Andrews V, Kuhns MC, McNamara AL. Hepatitis B core antigen antibody as an indicator of a low grade carrier state for hepatitis B virus in a Saudi Arabian blood donor population. Trasfus Sci 1997;18:49-53.
24. Gerlich WH. Diagnostic problems caused by HBsAg mutant-a consensus report of an expert meeting. Intervirology 2004;47:310-3.
25. Regan F, Hewitt P, Barbara J, Contreras M. Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group. Br Med J 2000;320:403-6.
26. Rakela J, Mosley JW, Aach GL, Gitnick GL, Hollinger FB, Stevens CE, et al. Viral hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. Gastroenterology 1980;78:1318.
27. Cossart YE, Kirsch S, Ismay SL. Posttransfusion hepatitis in Australia. Report of the Australian Red Cross study. Lancet 1982;1:208-13.
28. Katchaki JN, Siem TH, Brouwer R, Brandt KH, van der Waart M. Detection and significance of anti-HBc in the blood bank; preliminary results of a controlled prospective study. J Virol Methods 1980;2:119-25.
29. Koziol DE, Holland PV, Ailing DW, Melpolder JC, Solomon RE, Purcell RH, et al. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986;104:488-95.
30. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. The Italian Association for the Study of the Liver (A.I.S.E). Dig Liver Dis 2007;39:397-408.